Plasma protein analysis of patients with different B-cell lymphomas using high-content antibody microarrays

Christoph Schröder, Harish Srinivasan, Martin Sill, Jakob Linseisen, Kurt Fellenberg, Nikolaus Becker, Alexandra Nieters, Jörg D. Hoheisel

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: In this study, plasma samples from a multicentric case-control study on lymphoma were analyzed for the identification of proteins useful for diagnosis. Experimental design: The protein content in the plasma of 100 patients suffering from the three most common B-cell lymphomas and 100 control samples was studied with antibody microarrays composed of 810 antibodies that target cancer-associated proteins. Sample pools were screened for an identification of marker proteins. Then, the samples were analyzed individually to validate the usability of these markers. Results: More than 200 proteins with disease-associated abundance changes were found. The evaluation on individual patients confirmed some molecules as robust informative markers while others were inadequate for this purpose. In addition, the analysis revealed distinct subgroups for each of the three investigated B-cell lymphoma subtypes. With this information, we delineated a classifier that discriminates the different lymphoma entities. Conclusions and clinical relevance: Variations in plasma protein abundance permit discrimination between different patient groups. After validation on a larger study cohort, the findings could have diagnostic as well as differential diagnostic potential. Beside this, methodological aspects were critically evaluated, such as the value of sample pooling for the identification of biomarkers that are useful for a diagnosis on individual patients.

Original languageEnglish (US)
Pages (from-to)802-812
Number of pages11
JournalProteomics - Clinical Applications
Volume7
Issue number11-12
DOIs
StatePublished - Dec 1 2013

Fingerprint

B-Cell Lymphoma
Microarrays
Blood Proteins
Cells
Antibodies
Proteins
Lymphoma
Plasmas
Biomarkers
Design of experiments
Case-Control Studies
Classifiers
Cohort Studies
Research Design
Molecules
Neoplasms

Keywords

  • Antibody microarray
  • B-cell lymphoma
  • Chronic lymphocytic leukemia (CLL)
  • Diffuse large B-cell lymphoma (DLBCL)
  • Plasma profiling

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Plasma protein analysis of patients with different B-cell lymphomas using high-content antibody microarrays. / Schröder, Christoph; Srinivasan, Harish; Sill, Martin; Linseisen, Jakob; Fellenberg, Kurt; Becker, Nikolaus; Nieters, Alexandra; Hoheisel, Jörg D.

In: Proteomics - Clinical Applications, Vol. 7, No. 11-12, 01.12.2013, p. 802-812.

Research output: Contribution to journalArticle

Schröder, C, Srinivasan, H, Sill, M, Linseisen, J, Fellenberg, K, Becker, N, Nieters, A & Hoheisel, JD 2013, 'Plasma protein analysis of patients with different B-cell lymphomas using high-content antibody microarrays', Proteomics - Clinical Applications, vol. 7, no. 11-12, pp. 802-812. https://doi.org/10.1002/prca.201300048
Schröder, Christoph ; Srinivasan, Harish ; Sill, Martin ; Linseisen, Jakob ; Fellenberg, Kurt ; Becker, Nikolaus ; Nieters, Alexandra ; Hoheisel, Jörg D. / Plasma protein analysis of patients with different B-cell lymphomas using high-content antibody microarrays. In: Proteomics - Clinical Applications. 2013 ; Vol. 7, No. 11-12. pp. 802-812.
@article{c391e69c32c04b4f8746867427131169,
title = "Plasma protein analysis of patients with different B-cell lymphomas using high-content antibody microarrays",
abstract = "Purpose: In this study, plasma samples from a multicentric case-control study on lymphoma were analyzed for the identification of proteins useful for diagnosis. Experimental design: The protein content in the plasma of 100 patients suffering from the three most common B-cell lymphomas and 100 control samples was studied with antibody microarrays composed of 810 antibodies that target cancer-associated proteins. Sample pools were screened for an identification of marker proteins. Then, the samples were analyzed individually to validate the usability of these markers. Results: More than 200 proteins with disease-associated abundance changes were found. The evaluation on individual patients confirmed some molecules as robust informative markers while others were inadequate for this purpose. In addition, the analysis revealed distinct subgroups for each of the three investigated B-cell lymphoma subtypes. With this information, we delineated a classifier that discriminates the different lymphoma entities. Conclusions and clinical relevance: Variations in plasma protein abundance permit discrimination between different patient groups. After validation on a larger study cohort, the findings could have diagnostic as well as differential diagnostic potential. Beside this, methodological aspects were critically evaluated, such as the value of sample pooling for the identification of biomarkers that are useful for a diagnosis on individual patients.",
keywords = "Antibody microarray, B-cell lymphoma, Chronic lymphocytic leukemia (CLL), Diffuse large B-cell lymphoma (DLBCL), Plasma profiling",
author = "Christoph Schr{\"o}der and Harish Srinivasan and Martin Sill and Jakob Linseisen and Kurt Fellenberg and Nikolaus Becker and Alexandra Nieters and Hoheisel, {J{\"o}rg D.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1002/prca.201300048",
language = "English (US)",
volume = "7",
pages = "802--812",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "11-12",

}

TY - JOUR

T1 - Plasma protein analysis of patients with different B-cell lymphomas using high-content antibody microarrays

AU - Schröder, Christoph

AU - Srinivasan, Harish

AU - Sill, Martin

AU - Linseisen, Jakob

AU - Fellenberg, Kurt

AU - Becker, Nikolaus

AU - Nieters, Alexandra

AU - Hoheisel, Jörg D.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Purpose: In this study, plasma samples from a multicentric case-control study on lymphoma were analyzed for the identification of proteins useful for diagnosis. Experimental design: The protein content in the plasma of 100 patients suffering from the three most common B-cell lymphomas and 100 control samples was studied with antibody microarrays composed of 810 antibodies that target cancer-associated proteins. Sample pools were screened for an identification of marker proteins. Then, the samples were analyzed individually to validate the usability of these markers. Results: More than 200 proteins with disease-associated abundance changes were found. The evaluation on individual patients confirmed some molecules as robust informative markers while others were inadequate for this purpose. In addition, the analysis revealed distinct subgroups for each of the three investigated B-cell lymphoma subtypes. With this information, we delineated a classifier that discriminates the different lymphoma entities. Conclusions and clinical relevance: Variations in plasma protein abundance permit discrimination between different patient groups. After validation on a larger study cohort, the findings could have diagnostic as well as differential diagnostic potential. Beside this, methodological aspects were critically evaluated, such as the value of sample pooling for the identification of biomarkers that are useful for a diagnosis on individual patients.

AB - Purpose: In this study, plasma samples from a multicentric case-control study on lymphoma were analyzed for the identification of proteins useful for diagnosis. Experimental design: The protein content in the plasma of 100 patients suffering from the three most common B-cell lymphomas and 100 control samples was studied with antibody microarrays composed of 810 antibodies that target cancer-associated proteins. Sample pools were screened for an identification of marker proteins. Then, the samples were analyzed individually to validate the usability of these markers. Results: More than 200 proteins with disease-associated abundance changes were found. The evaluation on individual patients confirmed some molecules as robust informative markers while others were inadequate for this purpose. In addition, the analysis revealed distinct subgroups for each of the three investigated B-cell lymphoma subtypes. With this information, we delineated a classifier that discriminates the different lymphoma entities. Conclusions and clinical relevance: Variations in plasma protein abundance permit discrimination between different patient groups. After validation on a larger study cohort, the findings could have diagnostic as well as differential diagnostic potential. Beside this, methodological aspects were critically evaluated, such as the value of sample pooling for the identification of biomarkers that are useful for a diagnosis on individual patients.

KW - Antibody microarray

KW - B-cell lymphoma

KW - Chronic lymphocytic leukemia (CLL)

KW - Diffuse large B-cell lymphoma (DLBCL)

KW - Plasma profiling

UR - http://www.scopus.com/inward/record.url?scp=84890057028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890057028&partnerID=8YFLogxK

U2 - 10.1002/prca.201300048

DO - 10.1002/prca.201300048

M3 - Article

C2 - 24323458

AN - SCOPUS:84890057028

VL - 7

SP - 802

EP - 812

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 11-12

ER -